Introduction
This paper summarises the conclusions of an expert workshop on the health aspects of ®sh and n-3 polyunsaturated fatty acids (PUFA). The objectives of the workshop were to formulate scienti®cally sound conclusions on the health effects of (fatty) ®sh and the use of plant (alphalinolenic acid: C18:3 n-3) and marine n-3 PUFA, mainly eicosapentaenoic acid (EPA, C20:5 n-3) and docosahexaenoic acid (DHA, C22:6 n-3) in products for health reasons. The discussions were held on the basis of questions sent to the participants beforehand, and on brief introductions by participants. The discussions were held in four sessions: ®sh and health, health effects of plant and marine n-3 PUFA, human experiments with n-3 PUFA, and conclusions and recommendations.
Fish and health
Does the consumption of ®sh prevent coronary heart disease (CHD)? What is the optimal intake (amount and frequency) of ®sh? Several prospective observational studies and a randomised factorial trial showed that one serving of ®sh weekly may decrease the risk of fatal CHD by approximately 40% relative to no ®sh (Burr et al, 1989; Ascherio et al, 1995; Kromhout et al, 1995; Gillum et al, 1996; Daviglus et al, 1997) . Higher intakes did not provide greater protection. The prospective studies had a comparable methodology, compared either ®sh with no ®sh or low doses of marine n-3 PUFA (®sh oil) with no marine n-3 PUFA, and give a consistent picture of a reduction in CHD for the ®sh and marine n-3 PUFA groups. No inverse association between ®sh intake and fatal CHD has been found in a number of other prospective studies. This was probably due to the higher overall ®sh intakes (Lapidus et al, 1986; Morris et al, 1995) . These latter studies do not contradict the hypothesis of bene®cial effects of one serving of ®sh per week. They do strengthen, however, the conclusion that larger amounts of ®sh are not associated with increased bene®ts. Does fatty ®sh or the EPA/DHA content of the diet have a speci®c role in the prevention of CHD? Much of the ®sh consumed in the epidemiological studies was probably lean white ®sh. Combining data on the consumption of ®sh and the effects on CHD risk parameters with insights on mechanisms make it plausible, but not certain, that the very long chain n-3 PUFA were the ®sh components which caused the decrease in the risk of fatal CHD (Burr et al, 1989; Siscovick et al, 1995; Singh et al, 1997) .
Does consumption of ®sh protect against cancer?
There is no proof that ®sh consumption decreases cancer risk. In animal experiments high doses of marine n-3 PUFA inhibited the development of chemically-induced breast and colorectal cancers in the promotion phase, but probably not in the initiation phase. Epidemiological studies on ®sh and marine n-3 PUFA and cancer show variable results, but most studies show an inverse relationship between ®sh intake and the risk of breast and colorectal cancer (Boutron et al, 1991; Neuget et al, 1993; Sasaki et al, 1993) . These studies, however, provide little information on n-3 PUFA intakes. Recent epidemiological studies suggest an interaction between animal fat and ®sh from which might be hypothesised that marine n-3 PUFA protect against the effect of animal fat in colorectal cancer (Caygill et al, 1996) . In trials with patients prone to development of colorectal adenomas marine n-3 PUFA have been found to`normalise' hyperproliferation of mucosal crypt cells (Anti et al, 1992) .
Health effects of plant and marine n-3 PUFA Does alpha-linolenic acid protect against CHD? Epidemiological studies (Dolecek, 1992; Ascherio et al, 1996) and one clinical trial (De Lorgeril et al, 1994) suggest that intake of alpha-linolenic acid-rich food can decrease the risk of myocardial infarction and death. A relative de®ciency of n-3 PUFA may be present in a large proportion of the population and might be a factor in CHD. In the Health Professional Follow-up Study the relative risk of CHD for a one energy-% increase in alpha-linolenic acid was 0.41 after adjustment for standard risk factors and intake of ®bre and total fat (Ascherio et al, 1996) . An increase in arterial compliance by dietary alpha-linolenic acid, which might decrease the work load of the heart, might contribute to a reduced risk in CHD by alphalinolenic acid (Nestel et al, 1997) . Arterial compliance is also increased by marine n-3 PUFA in diabetics.
Can the bene®ts of EPA/DHA be obtained through alphalinolenic acid? If so, what is the conversion factor and on which criteria should this be judged? The effects of EPA/DHA can not be fully reproduced by alpha-linolenic acid, even in high doses. Conversion of alpha-linolenic acid into EPA might play a role in the protection against CHD (Allman et al, 1995; Freese & Mutanen, 1997) . However, the ef®cacy of alpha-linolenic acid in raising plasma EPA levels is low, alpha-linolenic acid is mainly oxidised, whereas EPA is incorporated into complex lipids. For every 10 g of dietary alpha-linolenic acid 0.5 ± 1 g EPA has been found to be incorporated into complex lipids (Emken et al, 1990; Valsta et al, 1996) . Supplementation with alpha-linolenic acid (10 g/d or more), however, minimally affected cellular phospholipid DHA levels (Mantzioris et al, 1994) . The conversion ratio is a crude measure of conversion plus incorporation and depends on the dose of alpha-linolenic acid and the content of other PUFA in the diet (mainly linoleic acid). Further studies are required to obtain quantitative conclusions on the effect of dietary alpha-linolenic acid on tissue contents of EPA and DHA.
Is the conversion of alpha-linolenic acid to very long chain PUFA in¯uenced by age or disease state? There are very little quantitative data available on the effects of age and disease on the conversion of alphalinolenic acid into very long chain PUFA (Bjerve et al, 1989; Nestel, 1992) . Recent, unpublished data indicate that the amount of very long chain PUFA derived from alphalinolenic acid in blood lipids does not differ between subjects over 60 y vs subjects under 35 y (Hornstra et al). Also, no difference has been demonstrated between term and pre-term infants in their ability to accumulate tissue EPA from dietary alpha-linolenic acid (Carnielli et al, 1996) . In some diseases, for example insulin de®cient diabetes, chronic alcoholism, and schizophrenia, the amount of EPA incorporated into tissue lipids from dietary alpha-linolenic acid may be decreased. In pregnancyinduced hypertension, the amount of very long chain PUFA in plasma and tissue phospholipids is increased .
Does alpha-linolenic acid affect cancer risk?
Data on alpha-linolenic acid and cancer in humans are scarce (Dolecek, 1992) . The results of animal studies are con¯icting (Johnston, 1995) . Increased intake of alphalinolenic acid was associated with increased prostate cancer incidence (Giovannucci et al, 1993; Gann et al, 1994) . This ®nding was recently con®rmed in a casecontrol study in Finland (Harvei et al, 1997) . However, other studies do not suggest an effect of alpha-linolenic acid intake on cancer mortality (Kolonel et al, 1988; Bougnoux et al, 1994) . The reason for the observed relationship between the alpha-linolenic acid intake and prostate cancer is not clear.
Human experiments with n-3 PUFA
What is the outcome on blood lipids and lipoproteins? Marine n-3 PUFA in doses of up to 7 g/d (average 3 ± 4 g/d) lower fasting blood triglycerides by approximately 25% (Harris, 1997) . VLDL lipids are most affected. There is evidence of a dose-response relation. The post-prandial triglyceride level is also lowered. LDL cholesterol increases by 4% in healthy subjects and by 7% in hypertriglyceridaemic patients (in addition to an increase in LDL particle size). HDL cholesterol increases by 3% in healthy people, but not in hypertriglyceridaemic patients. There are no indications for a modulating effect of linoleic acid on the effects of n-3 PUFA on blood lipids.
Dietary alpha-linolenic acid does not affect blood triglycerides, even at high intakes, and it lowers LDL cholesterol probably only when it replaces saturated fatty acids.
What is the outcome on neural development? Both very long chain n-3 and n-6 PUFA are important for neural development (Innis, 1991; Makrides et al, 1996) . An important issue still is the adequacy of alpha-linolenic acid in infant food as a precursor for DHA, in particular for preterm infants (Salem et al, 1996) . In these infants, formulas enriched with DHA were found to improve visual acuity and neuro-mental development. These effects disappeared at somewhat later age (Carlson et al, 1993; Innis et al, 1996) , but were of longer duration in other studies . An increased occurrence of sepsis or necrotising enterocolitis at enteral feeding with supplemented marine n-3 PUFA cannot be ruled out (Carlson et al, 1996) . Although DHA levels in brain autopsy tissue from babies fed formulas have been found to be lower than in breast-fed babies, it is not clear whether supplementation of formulas with marine n-3 PUFA has bene®cial effects on brain development.
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Due to the dif®culties in establishing the physiological consequences of DHA shortage in vivo, the question whether the addition of DHA alone or in combination with arachidonic acid to infant formulas confers a physiological bene®t to the infant has not yet been clari®ed. The same holds true for supplementation with alpha-linolenic acid at realistic doses to pregnant or lactating mothers in relation with the health of the new-born . It is also uncertain to what extent the ratio of linoleic acid to alpha-linolenic acid and/or the absolute amounts of linoleic acid and alpha-linolenic acid in the mothers' diet are of relevance to the health status of the foetus and breast-fed infant.
What is the outcome on lipid peroxidation? Oxidised LDL has been implicated in atherosclerosis. Oxidation of LDL leads to formation of thiobarbituric acid-reactive substances (TBARS). However, TBARS re¯ect both the content of PUFA and their oxidizability in LDL-particles. Moreover, appreciable amounts of TBARS may be present in foods and absorbed into the blood stream. Therefore, TBARS (in fact a rather unspeci®c method) should no longer be used as a measure for the oxidizability of LDL-particles in vivo.
Oxidizability of LDL is measured in vitro and may not re¯ect oxidation sensitivity of LDL in vivo. Linoleic acidenriched LDL particles are oxidised in vitro faster than LDL particles enriched with saturated or monounsaturated fatty acids (Reaven et al, 1994) . Inconsistent in vitro results have been published with respect to both plant and marine n-3 PUFA (Suzukawa et al, 1995; Brude et al, 1997) . Both n-6 and n-3 PUFA, however, should be regarded as sensitive to oxidation in vivo.
Since consumption of n-3 PUFA can be associated with a higher susceptibility to in vitro oxidizability of LDL, this should be accompanied by adequate amounts of antioxidants such as a -tocopherol (Muggli, 1994) . The established bene®cial effects of plant and marine n-3 PUFA on other risk factors for CHD likely outweigh any increased risk from oxidative changes.
What is the outcome on diabetes?
The effects of dietary n-3 PUFA on CHD risk factors in diabetics (type II) are not much different from those in nondiabetics (Axelrod et al, 1994) . In some studies marine n-3 PUFA induced a small increase in blood glucose levels in diabetics (Vessby et al, 1992) . Marine n-3 PUFA may reduce the insulin response (secretion) to glucose, but no consistent effect of marine n-3 PUFA on insulin sensitivity has been found. A possible interaction with the n-6 PUFA in the diet has not been adequately studied. Moderate doses of marine n-3 PUFA, and also ®sh consumption (Feskens et al, 1991) , may be bene®cial in diabetes, for example by an effect on triglycerides, but the use of large doses of marine n-3 PUFA should not be encouraged.
What is the outcome on blood pressure? Intake of marine n-3 PUFA can reduce blood pressure in hypertensive but less commonly in normotensive subjects. A minimum daily amount of 3 g may be needed for a signi®cant reduction (Appel et al, 1993; Morris et al, 1993) . Typically, 5 ± 6 g n-3 PUFA daily reduced systolic and diastolic blood pressure by 3.4 and 2.0 mm Hg, respectively, which can be expected to reduce risk for both stroke and CHD. In epidemiological studies no relation could be detected between ®sh intake and blood pressure. The limited data on alpha-linolenic acid show variable effects (Salonen, 1991; Nestel et al, 1997) .
What is the outcome on thrombosis/haemostasis? Because direct effects on arterial thrombosis can not be measured, surrogate endpoints have to be used to estimate effects on thrombotic risk. In endothelial cells (in-vitro studies) marine n-3 PUFA reduced the levels of mRNA coding for adhesion molecules and increased prostacyclin synthesis, whereas effects on nitric oxide release were inconsistent. Data on effects of marine n-3 PUFA and alpha-linolenic acid on coagulation and ®brinolysis are incomplete and inconsistent. Marine n-3 PUFA, but not alpha-linolenic acid, might reduce the level of circulating platelet aggregates. Summarising, there are insuf®cient data on the extent to which the anti-CHD effects of marine n-3 PUFA are mediated by changes in haemostasis (Knapp, 1997) .
What is the outcome on arrhythmias?
In animal models alpha-linolenic acid, EPA, DHA, and other PUFA reduced the susceptibility to ventricular ®bril-lation and in cardiac myocytes they had antiarrhythmic activity (Charnock, 1994; Leaf & Kang, 1996) . Effects on ion channels play a role. Epidemiological and clinical studies also suggest antiarrhythmic effects from the consumption of ®sh and marine n-3 PUFA (Siscovick et al, 1996; Christensen et al, 1997; Singh et al, 1997) . The evidence warrants controlled clinical trials on the effect of marine n-3 PUFA on ventricular ®brillation (the main cause of sudden death from acute heart attacks). No human data are available on the prevention of primary cardiac arrest by alpha-linolenic acid.
What is the outcome on immune function and in¯ammation? Marine n-3 PUFA moderately, but reproducibly, decrease pain and morning stiffness in rheumatoid arthritis (Kremer, 1996) and may also have bene®cial effects in renal transplantation (fewer complications) and in in¯ammatory bowel disease. Their effect on immunologic and in¯amma-tory diseases is probably due to the decrease in (effective) immune and in¯ammation mediators (eicosanoids and cytokines) (Endres & Von Schacky, 1996) . High dietary amounts of alpha-linolenic acid may also modestly decrease eicosanoid and cytokine synthesis, but do not have a clear effect on immunologic and in¯ammatory responses. There is no solid evidence that marine n-3 PUFA is effective in asthma and only weak evidence in psoriasis. There are no epidemiological data for ®sh and arthritis and there is only one study on alpha-linolenic acid and arthritis which showed that alpha-linolenic acid was ineffective. Due to effects of n-3 PUFA on immune and in¯ammation mediators, an increased intake of EPA might lead to a suppression of immune and in¯ammation responses, and consequently, to a decrease in host resistance to infections. However, no adverse effects of marine n-3 PUFA on infection in humans have been reported.
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Recommendations and conclusions
Are there scienti®c reasons to increase the current intake of n-3 fatty acids? There is suf®cient scienti®c evidence to support the view that marine n-3 PUFA can be bene®cial for health, especially for those who are at high risk for CHD. The meeting therefore agreed with the general recommendation to eat ®sh at least once a week. Fatty ®sh is preferable because of its high content of n-3 PUFA. People who do not eat ®sh could consider consuming marine n-3 PUFA equivalent to the amount obtained from fatty ®sh, namely 200 mg EPA plus DHA daily. This is equivalent to 10 ± 40 g of fatty ®sh per day. Pregnant women and neonates may require, in addition to linoleic acid and alpha-linolenic acid, some intake of very long chain n-3 PUFA to cover the needs for optimal growth and development.
Should there be separate recommendations for plant and marine n-3 PUFA? Separate recommendations for plant and marine n-3 PUFA may be needed due to their different physiologic effects. The meeting concluded that there are no scienti®c reasons to deviate from a recommendation for alpha-linolenic acid of one energy-%. Because the impact of an advice on intake of n-3 PUFA could be signi®cant, solid scienti®c underpinning through large-scale prospective studies and randomised controlled clinical trials is required. In addition, nutritional studies done so far with realistic amounts of EPA and DHA should be repeated with alphalinolenic acid.
Is the use of the n-3/n-6 ratio scienti®cally sensible? Experience with the polyunsaturated/saturated fatty acid ratio suggests that the use of a n-3/n-6 ratio will not be helpful. For instance, one might increase the n-3/n-6 ratio by lowering of the dietary linoleic acid level, but this does not have the same effect as increasing the n-3 PUFA level. The background of the use of the ratio is that the absolute amounts of n-3 PUFA in the Western diet might be too low and that the conversion of alpha-linolenic acid to DHA can be decreased by increasing the dietary amount of linoleic acid. Although the latter may be true, the absolute dietary amount of linoleic acid as such is important for CHD and not the ratio to n-3 PUFA.
Furthermore, alpha-linolenic acid and marine n-3 PUFA have distinct physiological effects and can not replace each other. However, the n-3/n-6 ratio is being discussed widely and is therefore dif®cult to ignore. The meeting concluded that there should be separate recommendations for alphalinolenic acid, marine n-3 PUFA and linoleic acid and that the n-3/n-6 ratio should not be used.
